

Striving for Consensus: Current and Future Management of Metastatic Non-Small Cell Lung Cancer in Patients Who Experience Disease Progression on Immune Checkpoint Inhibitor Therapy

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Which of the following is targeted by antibody-drug conjugate datopotamab deruxtecan?
 - a. HER2
 - b. Nectin-4
 - c. TIGIT
 - d. TROP2
 - e. CEACAM5
2. The Phase III REVEL trial evaluated the addition of ramucirumab to docetaxel versus docetaxel alone in which subgroup of patients with metastatic NSCLC?
 - a. Patients with nonsquamous histology
 - b. Patients with squamous histology
 - c. Both a and b
3. The ongoing Phase III Pragmatica-Lung (SWOG-S2302) study is evaluating which of the following agents in combination with pembrolizumab versus standard treatment for patients with Stage IV or recurrent NSCLC previously treated with immunotherapy?
 - a. Bevacizumab
 - b. Cabozantinib
 - c. Lenvatinib
 - d. Ramucirumab
 - e. Sitravatinib
4. Which of the following treatment-emergent adverse events was most prominent among patients treated with triplet therapy (Dato-DXd/pembrolizumab/chemotherapy) on the TROPION-Lung02 trial?
 - a. Alopecia
 - b. Nausea
 - c. Neutropenia
 - d. Insomnia
5. Tumor treating fields promote antitumor activity by directly affecting which of the following cellular processes?
 - a. Cell division
 - b. Protein synthesis
 - c. Ion transport
 - d. Adhesion to matrix